Dr. Hill Discusses the Progression of CLL Treatment

Brian T. Hill, MD, PhD
Published: Thursday, Nov 08, 2018



Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the progression of treatment of patients with chronic lymphocytic leukemia (CLL).

Beyond the BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence), Hill says that recent data have shown potential for other agents in CLL. One of these agents is venetoclax (Venclexta), which demonstrated a survival advantage over bendamustine in patients with advanced CLL. Venetoclax is highly active, and with proper dose-escalation, Hill says that it can be safely administered without any real risk for tumor lysis syndrome.

In light of these results, Hill says that the days of chemotherapy as a treatment for patients with CLL are dwindling. Although, if chemotherapy is going to be used, it should only be used once. From there, clinicians should think about moving to the targeted agents that are available. Right now, BTK inhibitors are the go-to therapy for most patients.


Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the progression of treatment of patients with chronic lymphocytic leukemia (CLL).

Beyond the BTK inhibitors ibrutinib (Imbruvica) and acalabrutinib (Calquence), Hill says that recent data have shown potential for other agents in CLL. One of these agents is venetoclax (Venclexta), which demonstrated a survival advantage over bendamustine in patients with advanced CLL. Venetoclax is highly active, and with proper dose-escalation, Hill says that it can be safely administered without any real risk for tumor lysis syndrome.

In light of these results, Hill says that the days of chemotherapy as a treatment for patients with CLL are dwindling. Although, if chemotherapy is going to be used, it should only be used once. From there, clinicians should think about moving to the targeted agents that are available. Right now, BTK inhibitors are the go-to therapy for most patients.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x